1. Home
  2. FULC vs PSNYW Comparison

FULC vs PSNYW Comparison

Compare FULC & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FULC
  • PSNYW
  • Stock Information
  • Founded
  • FULC 2015
  • PSNYW 2017
  • Country
  • FULC United States
  • PSNYW Sweden
  • Employees
  • FULC N/A
  • PSNYW 2547
  • Industry
  • FULC Biotechnology: Pharmaceutical Preparations
  • PSNYW Auto Manufacturing
  • Sector
  • FULC Health Care
  • PSNYW Consumer Discretionary
  • Exchange
  • FULC Nasdaq
  • PSNYW Nasdaq
  • Market Cap
  • FULC 375.4M
  • PSNYW 348.4M
  • IPO Year
  • FULC 2019
  • PSNYW N/A
  • Fundamental
  • Price
  • FULC $6.45
  • PSNYW $0.15
  • Analyst Decision
  • FULC Buy
  • PSNYW
  • Analyst Count
  • FULC 8
  • PSNYW 0
  • Target Price
  • FULC $7.13
  • PSNYW N/A
  • AVG Volume (30 Days)
  • FULC 984.6K
  • PSNYW 43.4K
  • Earning Date
  • FULC 07-29-2025
  • PSNYW 03-06-2025
  • Dividend Yield
  • FULC N/A
  • PSNYW N/A
  • EPS Growth
  • FULC N/A
  • PSNYW N/A
  • EPS
  • FULC N/A
  • PSNYW N/A
  • Revenue
  • FULC N/A
  • PSNYW $2,034,261,000.00
  • Revenue This Year
  • FULC N/A
  • PSNYW N/A
  • Revenue Next Year
  • FULC N/A
  • PSNYW $79.49
  • P/E Ratio
  • FULC N/A
  • PSNYW N/A
  • Revenue Growth
  • FULC 2752.05
  • PSNYW N/A
  • 52 Week Low
  • FULC $2.32
  • PSNYW $0.09
  • 52 Week High
  • FULC $10.13
  • PSNYW $0.61
  • Technical
  • Relative Strength Index (RSI)
  • FULC 39.24
  • PSNYW 52.93
  • Support Level
  • FULC $6.47
  • PSNYW $0.15
  • Resistance Level
  • FULC $7.00
  • PSNYW $0.18
  • Average True Range (ATR)
  • FULC 0.57
  • PSNYW 0.01
  • MACD
  • FULC -0.12
  • PSNYW 0.00
  • Stochastic Oscillator
  • FULC 5.42
  • PSNYW 46.26

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.

Share on Social Networks: